NYSE:PRME Prime Medicine (PRME) Stock Price, News & Analysis $4.21 -0.14 (-3.22%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.18 -0.03 (-0.59%) As of 07/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Prime Medicine Stock (NYSE:PRME) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prime Medicine alerts:Sign Up Key Stats Today's Range$4.18▼$4.3650-Day Range$1.17▼$4.8052-Week Range$1.11▼$5.95Volume2.16 million shsAverage Volume2.32 million shsMarket Capitalization$566.23 millionP/E RatioN/ADividend YieldN/APrice Target$9.25Consensus RatingModerate Buy Company Overview Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. Read More Prime Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScorePRME MarketRank™: Prime Medicine scored higher than 77% of companies evaluated by MarketBeat, and ranked 246th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoveragePrime Medicine has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Prime Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($1.68) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted39.00% of the float of Prime Medicine has been sold short.Short Interest Ratio / Days to CoverPrime Medicine has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Prime Medicine has recently increased by 8.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth.Read more about Prime Medicine's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted39.00% of the float of Prime Medicine has been sold short.Short Interest Ratio / Days to CoverPrime Medicine has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Prime Medicine has recently increased by 8.98%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.77 News SentimentPrime Medicine has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search Interest33 people have searched for PRME on MarketBeat in the last 30 days. This is an increase of 313% compared to the previous 30 days.MarketBeat Follows12 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $110,250.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.93% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME Stock News HeadlinesWhat is Wedbush's Estimate for Prime Medicine Q2 Earnings?July 20, 2025 | americanbankingnews.comPrime Medicine (NYSE:PRME) Receives Outperform Rating from WedbushJuly 18, 2025 | americanbankingnews.comAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation. | Paradigm Press (Ad)Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic AdvancementsJuly 17, 2025 | tipranks.comPrime Medicine Shares Drop After New Funding, Equity InvestmentJuly 16, 2025 | marketwatch.comCystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing TherapyJuly 16, 2025 | businesswire.comPrime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic FibrosisJuly 16, 2025 | globenewswire.comPrime Medicine: Pressing Forward With Lead Liver Targeting IndicationsJuly 7, 2025 | seekingalpha.comSee More Headlines PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $2.92 on January 1st, 2025. Since then, PRME shares have increased by 44.2% and is now trading at $4.21. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NYSE:PRME) announced its quarterly earnings results on Friday, March, 7th. The company reported ($1.65) EPS for the quarter. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an IPO on Thursday, October 20th 2022. The company issued 10,294,118 shares at $16.00-$18.00 per share. Who are Prime Medicine's major shareholders? Top institutional investors of Prime Medicine include Palumbo Wealth Management LLC (0.14%), CWM LLC (0.03%), Wealth Enhancement Advisory Services LLC (0.02%) and Vanguard Personalized Indexing Management LLC (0.02%). Insiders that own company stock include David R Liu, Robert Nelsen and 2019 Gp LLC Gv. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prime Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Intel (INTC), NVIDIA (NVDA), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings3/07/2025Today7/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:PRME CIK1894562 Webprimemedicine.com Phone617-564-0013FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Price Target for Prime Medicine$9.25 High Price Target$18.00 Low Price Target$1.50 Potential Upside/Downside+119.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.13 million Net MarginsN/A Pretax Margin-27,406.12% Return on Equity-107.87% Return on Assets-74.97% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio6.50 Sales & Book Value Annual Sales$3.85 million Price / Sales147.23 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book3.07Miscellaneous Outstanding Shares134,496,000Free Float100,378,000Market Cap$566.23 million OptionableOptionable Beta2.33 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:PRME) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.